Optimizing Pain Assessment: Tools and Risk Mitigation


Experts discuss opioid use with a focus on validated assessment tools, monitoring strategies, and risk mitigation practices, delving into the complexities of pain scales and emphasizing the need for functional assessments.

This is a video synopsis/summary of a Practice Pearls featuring Ryan Haumschild, PharmD, MS, MBA, CPEL; Megan Mitchell, PharmD, MS; Stephanie Abel, PharmD, BCPS; and Jennifer Grate, CPhT.

Haumschild discusses the importance of evaluating and incorporating validated assessment tools for opioid use management. Abel addresses the limitations of unidimensional pain scales and emphasizes the need for functional pain assessment tools, especially for cognitively intact adults. She highlights challenges in pediatric and nonverbal patient populations, suggesting the evaluation of literature and patient needs for appropriate tool selection. Haumschild acknowledges the need for more validated scales across diverse populations. Mitchell explores risk assessment tools and their purpose in identifying patients at higher risk for opioid misuse. She mentions tools like the Opioid Risk Tool and the Risk Index for Overdose or Serious Opioid-Induced Respiratory Depression. Mitchell emphasizes the importance of considering the clinical impact of identifying a patient as high risk and aligning risk stratification with actionable goals. Haumschild emphasizes the significance of having clear goals and ensuring that risk stratification leads to actionable interventions in patient care.

This summary was AI-generated and reviewed by Pharmacy Times® editorial staff.

Related Videos
Collaborative Care Team for Diabetes, Cardiovascular Disease | Image Credit: Production Perig - stock.adobe.com
Video 14 - "Closing Remarks on RSV Vaccinations"
Video 13 - "Understanding RSV Infection Patterns and Seasonal Outbreaks"
Video 12 - "Empowering RSV Patients: Essential Vaccine Education Resources"
Video 11 - "Unmet Needs in Prevention and Management of RSV"
Video 12 - "Collaborative Care: Key Stakeholders in HE Treatment and Recovery"
Video 11 - "Optimizing Transitions of Care for Hepatic Encephalopathy Patients"
Video 10 - "Valuable Metrics and Improving Adherence in Patients With ASCVD"
Video 9 - "The Role of Pharmacists in Treating Very High-Risk ASCVD"
Video 6 - "evaluating CDK4/6 inhibitor safety profiles"
Related Content
© 2024 MJH Life Sciences

All rights reserved.